Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker
Year: 2020
Type: article
Study design: Observational Study
Abstract: Elevated serum lactate dehydrogenase (sLDH) is associated with poor clinical outcomes in patients with stage IV metastatic melanoma (MM). It is currently unknown if sLDH elevation correlates with distinct molecular, metabolic, or immune features of melanoma metastases. The identification of such features may identify rational therapeutic strategies for patients with elevated sLDH. Thus, we obtained sLDH levels for melanoma patients with metastases who had undergone molecular and/or immune profiling. Our analysis of multi-omics data from independent cohorts of melanoma metastases showed that elevated sLDH was not significantly associated with differences in immune cell infiltrate, point mutations, DNA copy number variations, promoter methylation, RNA expression, or protein expression in melanoma metastases. The only significant association observed for elevated sLDH was with the number of metastatic sites of disease. Our data support that sLDH correlates with disease burden, but not specific molecular or immunological phenotypes, in metastatic melanoma.
Source: Cancer Medicine
DOI: 10.1002/cam4.3474
Authors: Grant M. Fischer, Fernando C. L. Carapeto, Aron Y. Joon, Lauren E. Haydu, Huiqin Chen, Fuchenchu Wang, John S. Van Arnam, Jennifer L. McQuade, Khalida Wani, John M. Kirkwood, John F. Thompson, Michael T. Tetzlaff, Alexander J. Lazar, Hussein A. Tawbi, Jeffrey E. Gershenwald, Richard A. Scolyer, Georgina V. Long, Michael A. Davies
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,750
Funders: Cancer Prevention and Research Institute of Texas, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, AIM at Melanoma, University of Texas Health Science Center at Houston, Melanoma Institute Australia, National Institutes of Health, University of Texas MD Anderson Cancer Center, National Cancer Institute, National Center for Advancing Translational Sciences
Awards: The University of Texas MD Anderson Cancer Center SPORE in Melanoma, Exploiting molecular and metabolic dependencies to optimize personalized therapeutic approaches for melanomas, Targeting The Glycolysis Pathway To Overcome Resistance To Cancer Immunotherapy, G580208524, Center for Clinical and Translational Sciences (CCTS), G840739938, G9000059764, Cancer Center Support Grant, A High-Throughput Model for Human Melanoma
OpenAlex ID: W3091360746